IRCT20120520009801N9招募中2 期
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting (CABG) or heart valve replacement: a triple-blind, randomized, placebo-controlled trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 70 years（—）
- 性别
- All
入选标准
- •Candidates for heart surgery including CABG or valve replacement
- •70 yr > age > 18 yr
- •Taking ACEIs/ARBs, beta-blockers, statins and aspirin for CABG patients
排除标准
- •History of taking empagliflozin drug before surgery
- •Severe heart failure (NYHA Class IV)
- •Renal failure (30 = GFR)
- •Hepatic failure (hepatic enzymes > 3 times of upper normal limit )
- •Have pacemaker
- •Have AF rhythm
- •History of heart surgery
- •Very thin people (BMI = 18.5 kg/m2)
研究者
相似试验
招募中
3 期
Evaluating the effects of empagliflozin in preventing myocardial damage in patients undergoing percutaneous coronary interventioCardiovascular disease.Cardiovascular disease, unspecified429.2IRCT20221102056378N1Tabriz University of Medical Sciences90
尚未招募
3 期
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
已完成
1 期
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
已完成
3 期
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
尚未招募
3 期
Effect of Empagliflozin as adjunctive therapy on serum level of oxidative stress biomarkersIRCT20120215009014N486Hamedan University of Medical Sciences80